These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 26333844

  • 1. De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation.
    Koch M, Wiech T, Marget M, Peine S, Thude H, Achilles EG, Fischer L, Lehnhardt A, Thaiss F, Nashan B.
    Clin Transplant; 2015 Nov; 29(11):1021-8. PubMed ID: 26333844
    [Abstract] [Full Text] [Related]

  • 2. ABO incompatible renal transplantation without antibody removal using conventional immunosuppression alone.
    Masterson R, Hughes P, Walker RG, Hogan C, Haeusler M, Robertson AR, Millar R, Suh N, Cohney SJ.
    Am J Transplant; 2014 Dec; 14(12):2807-13. PubMed ID: 25389083
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of antigen-specific immunoadsorption and rebound of anti-A/B antibodies in ABO-incompatible kidney transplantation.
    Genberg H, Kumlien G, Wennberg L, Tyden G.
    Nephrol Dial Transplant; 2011 Jul; 26(7):2394-400. PubMed ID: 21558429
    [Abstract] [Full Text] [Related]

  • 4. High B-cell activating factor is not associated with worse 3-year graft outcome in blood group-incompatible kidney transplantation with rituximab induction.
    Lehnhardt AM, Strecker M, Eiermann T, Marget M, Thaiss F, Nashan B, Koch M.
    Clin Transplant; 2015 Apr; 29(4):359-64. PubMed ID: 25627801
    [Abstract] [Full Text] [Related]

  • 5. One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience.
    Zschiedrich S, Jänigen B, Dimova D, Neumann A, Seidl M, Hils S, Geyer M, Emmerich F, Kirste G, Drognitz O, Hopt UT, Walz G, Huber TB, Pisarski P, Kramer-Zucker A.
    Nephrol Dial Transplant; 2016 Apr; 31(4):663-71. PubMed ID: 26610596
    [Abstract] [Full Text] [Related]

  • 6. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J, Machida Y, Iwai T, Kuwabara N, Kabei K, Naganuma T, Kumada N, Kawashima H, Nakatani T.
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [Abstract] [Full Text] [Related]

  • 7. Favorable results in ABO-incompatible renal transplantation without B cell-targeted therapy: Advantages and disadvantages of rituximab pretreatment.
    Okada M, Watarai Y, Iwasaki K, Murotani K, Futamura K, Yamamoto T, Hiramitsu T, Tsujita M, Goto N, Narumi S, Takeda A, Morozumi K, Uchida K, Kobayashi T.
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28792635
    [Abstract] [Full Text] [Related]

  • 8. ABO-incompatible kidney transplantation.
    Takahashi K, Saito K.
    Transplant Rev (Orlando); 2013 Jan; 27(1):1-8. PubMed ID: 22902167
    [Abstract] [Full Text] [Related]

  • 9. Outcome of ABO Blood Type-Incompatible Living-Related Donor Kidney Transplantation Under a Contemporary Immunosuppression Strategy in Japan.
    Hamano I, Hatakeyama S, Fujita T, Murakami R, Hamaya T, Togashi K, Suzuki Y, Yamamoto H, Yoneyama T, Yoneyama T, Hashimoto Y, Narumi S, Tomita H, Ohyama C.
    Transplant Proc; 2020 Jan; 52(6):1700-1704. PubMed ID: 32448659
    [Abstract] [Full Text] [Related]

  • 10. ABO incompatible living donor kidney transplantation in Korea: highly uniform protocols and good medium-term outcome.
    Kong JM, Ahn J, Park JB, Chung BH, Yang J, Kim JK, Huh KH, Kim JM.
    Clin Transplant; 2013 Jan; 27(6):875-81. PubMed ID: 24118271
    [Abstract] [Full Text] [Related]

  • 11. ABO-incompatible pediatric kidney transplantation without antibody removal.
    Kawamura T, Hamasaki Y, Takahashi Y, Hashimoto J, Kubota M, Muramatu M, Itabashi Y, Hyodo Y, Ohashi Y, Aikawa A, Sakai K, Shishido S.
    Pediatr Nephrol; 2020 Jan; 35(1):95-102. PubMed ID: 31673829
    [Abstract] [Full Text] [Related]

  • 12. Increase of infectious complications in ABO-incompatible kidney transplant recipients--a single centre experience.
    Habicht A, Bröker V, Blume C, Lorenzen J, Schiffer M, Richter N, Klempnauer J, Haller H, Lehner F, Schwarz A.
    Nephrol Dial Transplant; 2011 Dec; 26(12):4124-31. PubMed ID: 21622990
    [Abstract] [Full Text] [Related]

  • 13. Potent immunosuppression for ABO-incompatible renal transplantation may not be a risk factor for malignancy.
    Yamamoto T, Kawaguchi T, Watarai Y, Tujita M, Hiramitsu T, Nanmoku K, Goto N, Katayama A, Kobayashi T, Uchida K.
    Transplant Proc; 2012 Jan; 44(1):210-3. PubMed ID: 22310616
    [Abstract] [Full Text] [Related]

  • 14. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y, Iwadoh K, Ogawa Y, Miki K, Kato Y, Kai K, Sannomiya A, Koyama I, Kitajima K, Nakajima I, Fuchinoue S.
    PLoS One; 2019 Jan; 14(10):e0224203. PubMed ID: 31644555
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S, Hwang E, Park S, Park U, Kim H, Cho W.
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [Abstract] [Full Text] [Related]

  • 16. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J, Dietze N, Spetzler VN, Fischer L, Achilles EG, Li J, Scheidat S, Thaiss F, Nashan B, Koch M.
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [Abstract] [Full Text] [Related]

  • 17. Outcomes of Pediatric ABO-incompatible Living Kidney Transplantations From 2002 to 2015: An Analysis of the Japanese Kidney Transplant Registry.
    Hattori M, Mieno M, Shishido S, Aikawa A, Ushigome H, Ohshima S, Takahashi K, Hasegawa A, Japan Society for Transplantation and Japanese Society for Clinical Renal Transplantation.
    Transplantation; 2018 Nov; 102(11):1934-1942. PubMed ID: 29781948
    [Abstract] [Full Text] [Related]

  • 18. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K, Saito K, Takahara S, Fuchinoue S, Yagisawa T, Aikawa A, Watarai Y, Yoshimura N, Tanabe K, Morozumi K, Shimazu M, IDEC-C2B8 ABO-I KTx Study Group.
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [Abstract] [Full Text] [Related]

  • 19. Risk factors for postoperative bleeding in ABO-incompatible kidney transplantation.
    Kim MH, Jun KW, Hwang JK, Kim JI, Chung BH, Choi BS, Kim YS, Yang CW, Moon IS.
    Clin Transplant; 2015 Apr; 29(4):365-72. PubMed ID: 25646784
    [Abstract] [Full Text] [Related]

  • 20. ABO-incompatible kidney transplantation: first cases in Turkey.
    Tuncer M, Yücetin L, Tekin S, Demirbas A.
    Transplant Proc; 2012 Apr; 44(6):1703-5. PubMed ID: 22841248
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.